Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old
David Fitzpatrick, Mariano Young, Kari Yacisin, Kathleen McElwee, Todd Belanger, Kelly A. Belanger, Yahong Peng, Dung-Yang Lee, William C. Gruber, Daniel A. Scott, Wendy Watson
Topics & Concepts
ImmunogenicityMedicineAdverse effectVaccinationTolerabilityDiscontinuationRandomized controlled trialDosingReactogenicityPharmacologyImmunologyInternal medicineImmune systemPneumonia and Respiratory InfectionsSARS-CoV-2 and COVID-19 ResearchInfluenza Virus Research Studies